Pramod Kumar Manjhi
Overview
Explore the profile of Pramod Kumar Manjhi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghorui A, Chowdhry B, Manjhi P, Kumar P, Kumar C
BMJ Paediatr Open
. 2024 Oct;
8(1).
PMID: 39395818
Objective: Neonatal jaundice is the most common cause of neonatal morbidity and rehospitalisation in the first week of life, affecting approximately 60% of term and 80% of preterm neonates, with...
2.
Payra S, Harsha D, Kumar K, Manjhi P, Singh S, Kumar R, et al.
Clin Drug Investig
. 2024 Sep;
44(9):667-685.
PMID: 39302585
Background And Objectives: Dolutegravir has been used as a first-line anti-human immunodeficiency virus drug because of its better efficacy compared with other counterpart medicines. However, making a unanimous decision on...
3.
Payra S, Manjhi P, Singh S, Kumar R, Singh S, Kumar A, et al.
HIV Med
. 2023 Oct;
25(3):322-331.
PMID: 37821095
Background: At present, combination antiretroviral therapy (cART) is the mainstay for the treatment of people living with HIV/AIDS. cART can suppress the viral load to a minimal level; however, the...
4.
Manjhi P, Kumar R, Priya A, Rab I
Maedica (Bucur)
. 2021 Oct;
16(2):163-169.
PMID: 34621334
Concomitant atrial fibrillation (AF) in non-ST segment elevation acute coronary syndrome (NSTE-ACS) patients complicates the decision-making process regarding short- and long-term antithrombotic strategies. Patient profiles and usage rates of different...
5.
Ravikirti , Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, et al.
J Pharm Pharm Sci
. 2021 Jul;
24:343-350.
PMID: 34265236
Background: There has been a growing interest in ivermectin ever since it was reported to have an in-vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This trial was...
6.
Manjhi P, Sinha R, Kumar M, Sinha K
J Clin Diagn Res
. 2014 Nov;
8(9):HC01-4.
PMID: 25386453
Background: The conventionally used topical antiscabetics have poor compliance. Ivermectin, an oral antiparasitic drug, has been shown to be an effective scabicide and could be a useful substitute. This study...